The association between loss of Medicare, immunosuppressive medication use, and kidney transplant outcomes
- PMID: 30838768
- PMCID: PMC6785998
- DOI: 10.1111/ajt.15293
The association between loss of Medicare, immunosuppressive medication use, and kidney transplant outcomes
Abstract
Kidney transplant recipients aged <65 years qualify for Medicare coverage, but coverage ends 3 years posttransplant. We determined the association between timing of Medicare loss and immunosuppressive medication fills and kidney allograft loss. Using data from the Scientific Registry of Transplant Recipients (SRTR), US Renal Data System, and Symphony pharmacy fill database, we analyzed 78 861 Medicare-covered, kidney-alone recipients aged <65 years, and assessed the timing of Medicare loss posttransplant: early (<3 years), on-time (at 3 years), or late (>3 years). Immunosuppressant use was measured as medication possession ratio (MPR). Allograft loss was assessed using SRTR data. MPR was lower for recipients with early or late Medicare loss compared with no coverage loss for all immunosuppressive medication types. For calcineurin inhibitors, early Medicare loss was associated with a 53% to 86% lower MPR. On-time Medicare loss was not associated with a lower MPR. When recipients were matched by age, posttransplant timing of Medicare loss, and donor risk, the hazard of allograft loss was 990% to 1630% higher after early Medicare loss, and 140% to 740% higher after late Medicare loss, with no difference in the hazard for on-time Medicare loss. Ensuring ongoing Medicare access before and after 3 years posttransplant could affect graft survival.
Keywords: Scientific Registry for Transplant Recipients (SRTR); clinical research/practice; insurance - public; kidney transplantation/nephrology.
Published 2019. This article is a U.S. Government work and is in the public domain in the USA.
Conflict of interest statement
DISCLOSURE
The authors of this manuscript have no conflicts of interest to disclose as described by the
Figures
Comment in
-
Medicare immunosuppressive drug coverage bills-Can we afford them?Am J Transplant. 2019 Jul;19(7):1877-1878. doi: 10.1111/ajt.15345. Epub 2019 Apr 10. Am J Transplant. 2019. PMID: 30848535 No abstract available.
Similar articles
-
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.J Am Soc Nephrol. 2020 Jan;31(1):218-228. doi: 10.1681/ASN.2019070646. Epub 2019 Nov 8. J Am Soc Nephrol. 2020. PMID: 31704739 Free PMC article.
-
Refill-Based Medication Use Quality Measures in Kidney Transplant Recipients: Examination of Proportion of Days Covered and Medication Possession Ratio.J Manag Care Spec Pharm. 2018 Apr;24(4):367-372. doi: 10.18553/jmcp.2018.24.4.367. J Manag Care Spec Pharm. 2018. PMID: 29578851 Free PMC article.
-
Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients.Am J Transplant. 2009 Nov;9(11):2497-504. doi: 10.1111/j.1600-6143.2009.02793.x. Epub 2009 Aug 14. Am J Transplant. 2009. PMID: 19681814
-
Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.Clin J Am Soc Nephrol. 2013 Jul;8(7):1258-66. doi: 10.2215/CJN.09440912. Epub 2013 Apr 4. Clin J Am Soc Nephrol. 2013. PMID: 23559679 Free PMC article. Review.
-
Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?Paediatr Drugs. 2011 Feb 1;13(1):49-69. doi: 10.2165/11538530-000000000-00000. Paediatr Drugs. 2011. PMID: 21162600 Review.
Cited by
-
Individual- and Community-Level Socioeconomic Status and Deceased Donor Renal Transplant Outcomes.J Racial Ethn Health Disparities. 2023 Nov 14. doi: 10.1007/s40615-023-01851-8. Online ahead of print. J Racial Ethn Health Disparities. 2023. PMID: 37962790
-
Porcine anti-human lymphocyte immunoglobulin depletes the lymphocyte population to promote successful kidney transplantation.Front Immunol. 2023 Mar 9;14:1124790. doi: 10.3389/fimmu.2023.1124790. eCollection 2023. Front Immunol. 2023. PMID: 36969156 Free PMC article.
-
Pandemic-related unemployment impacts transplant in the US.Am J Transplant. 2020 Aug;20(8):1957-1958. doi: 10.1111/ajt.16202. Am J Transplant. 2020. PMID: 32735395 Free PMC article.
-
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.J Am Soc Nephrol. 2020 Jan;31(1):218-228. doi: 10.1681/ASN.2019070646. Epub 2019 Nov 8. J Am Soc Nephrol. 2020. PMID: 31704739 Free PMC article.
References
-
- Port F. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270(11): 1339–1343. - PubMed
-
- Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50(1):235–242. - PubMed
-
- Wolfe R, Ashby V, Milford E, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725–1730. - PubMed
-
- Fujisawa M, Ichikawa Y, Yoshiya K, et al. Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey. Urology. 2000;56(2):201–206. - PubMed
-
- Valderrábano F, Jofre R, López-Gómez J. Quality of life in end-stage renal disease patients. Am J Kidney Dis. 2001;38(3):443–464. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
